Allergen immunotherapy as add-on to biologic agents

Carlo Lombardi, Giorgio W. Canonica, Giovanni Passalacqua

Research output: Contribution to journalArticlepeer-review


PURPOSE OF REVIEW: In this review, we sought to outline many of the recent evidences about the available clinical trials in which biologic agents [i.e. omalizumab (OMA)] were associated as add-on to allergen-specific immunotherapy (AIT).

RECENT FINDINGS: The available literature shows that OMA may be a valuable option as add-on to AIT for respiratory allergy, or food desensitization, especially in the escalation or build-up phases, in which adverse events are more commonly expected. The encouraging data for hymenoptera venom allergy remain limited to case reports, and no structured clinical trial is available.

SUMMARY: Over the past decade, studies of OMA used with AIT have shown promising results. Today, big randomized, double-blind, placebo-controlled trials are needed to better select those patients who would benefit from the addition of OMA (or other biologic agents) to AIT, as well as optimal dosing schedules, optimal duration of treatments and, finally, adequate evaluation about pharmacoeconomic aspects.

Original languageEnglish
Pages (from-to)502-508
Number of pages7
JournalCurrent Opinion in Allergy and Clinical Immunology
Issue number6
Publication statusPublished - Dec 1 2018

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Allergen immunotherapy as add-on to biologic agents'. Together they form a unique fingerprint.

Cite this